Refolding of the recombinant protein Sm29, a step toward the production of the vaccine candidate against schistosomiasis

Chura-Chambi, Rosa Maria; Nakajima, Erika; Carvalho, Roberta Rodrigues de; Miyasato, Patrícia A.; Oliveira, Sérgio C.; Morganti, Lígia; Martins, Elizabeth A. L.

doi:10.1016/j.jbiotec.2013.09.017

Cited by 14 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FSm14/29, Sm14 and Sm29 were given at doses of 20, 20 and 10 μg/mouse respectively while the poly(I:C) adjuvant was given at a dose of 50 μg/mouse. These concentrations were chosen based on previously published data for Sm14 and Sm29 [ 21 , 22 ]. Two negative control groups injected with sterile saline or poly(I:C) adjuvant were also included.…”

Section: Methodsmentioning

confidence: 99%

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

et al. 2015

View full text Add to dashboard Cite

BackgroundSchistosoma mansoni infection represents a major cause of morbidity and mortality in many areas of the developing world. Effective vaccines against schistosomiasis are not available and disease management relies mainly on treatment with the anthelmintic drug praziquantel. Several promising schistosomal antigens have been evaluated for vaccine efficacy such as Sm14, Sm29 and tetraspanins. However, most investigators examine these promising antigens in animal models individually rather than in properly adjuvanted antigen combinations.MethodsIn the present study, we made a recombinant fusion protein comprised of the promising schistosomal antigens Sm14 and Sm29. The fusion protein, FSm14/29, was administered to Swiss albino mice either unadjuvanted or adjuvanted with polyinosinic-polycytidylic acid adjuvant, poly(I:C). Mice were challenged with S. mansoni cercariae and different parasitological/immunological parameters were assessed seven weeks post-challenge. Data were analyzed using the ANOVA test with post-hoc Tukey-Kramer test.ResultsMice pre-immunized with unadjuvanted or poly(I:C)-adjuvanted fusion protein showed reduction of adult worm burden of 44.7 and 48.4%, respectively. In addition, significant reduction of tissue egg burdens was observed in mice immunized with the fusion protein when compared with the infected saline/adjuvant negative control groups and groups immunized with the individual Sm14 and Sm29 antigens. Light microscope and scanning electron microscope (SEM) investigation of adult worms recovered from FSm14/29-immunized mice revealed appreciable morphological damage and tegumental deformities. Histopathological examination of liver sections of immunized mice demonstrated reduced granulomatous and inflammatory reactions when compared with infected unvaccinated mice or mice immunized with the individual Sm14 and Sm29 antigens.ConclusionThe findings presented in this study highlight the importance of the fusion protein FSm14/29 as a potential vaccine candidate that is worthy of further investigation.

show abstract

Section: Methodsmentioning

confidence: 99%

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Schistosoma mansoni 29 kilodalton (Sm29) protein is a membrane-bounded Ag presents in the outer tegument surface of lung stage schistosomula and adult worms. It is one of the most expressed and exposed Ag ( Chura-Chambi et al, 2013 ; Cardoso et al, 2008 ). Specific Abs against Sm29 like IgG1 and IgG3 were detected in sera of patients living in endemic areas of Brazil, and significantly higher levels of these Abs were found in individuals who are resistant to re-infection ( Cardoso et al, 2006 ).…”

Section: Current Status Of Protein Vaccine Candidates Against mentioning

confidence: 99%

“…The refolded Ag presented a protective effect against S. mansoni development in immunized mice. The procedure can be scaled-up, allowing industrial production of Sm29 ( Chura-Chambi et al, 2013 ) (See Table 1 .)…”

Section: Current Status Of Protein Vaccine Candidates Against mentioning

confidence: 99%

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

Eyayu

Zeleke

Worku

2020

Parasite Epidemiology and Control

View full text Add to dashboard Cite

Schistosomiasis is an acute and chronic tropical parasitic disease caused by blood dwelling worm of the genus Schistosoma. It is the most destructive disease globally and is a major cause of morbidity and mortality for developing countries. Three main species of schistosomes infect human beings from which S. mansoni is the most common and widespread. Over the last several decades, chemotherapy using praziquantel has been a commonly used strategy for the treatment and control of schistosomiasis. However, control programs focused exclusively on chemotherapy have been challenging because of the frequency and rapidity of reinfection and these programs were expensive. Thus, new schistosomiasis control strategies will be needed. Vaccination strategy would be an ideal tool for a significant and sustainable reduction in the transmission and disease burden of schistosomiasis. An effective anti schistosome vaccine would greatly contribute to decreasing schistosomiasis-associated morbidity via protective immune responses leading to reduced worm burdens and decreased egg production. Vaccine development is a long process that can take decades. There have been three candidate vaccines that have been produced by Good Manufacturing Procedure and entered human clinical trials for S. mansoni are Sm14, SmTSP-2, and Sm-p80. Other candidates that are in pre-clinical trials at various stages include paramyosin, Sm29, SmKI-1, and Sm23. Since the growth of several new technologies, including genomics, transcriptomics, microarrays, immunomic profiling, and proteomics, have helped in the identification of promising new target schistosome antigens. Therefore, this review considers the present status of protein vaccine candidates against Schistosoma mansoni and provides some insight on prospects vaccine design and discovery.

show abstract

“…Similarly, fusing Sm29 with Sm -TSP-2 resulted in an increased reduction (from 22 to 35 %) in the number of worms, a higher titre of IgG1 and IgG2 antibodies and increased levels of IFNγ and TNFα than Sm29 alone in challenged mice [ 43 , 44 ]. In a further advance, recombinant Sm29 was subjected to high hydrostatic pressure which dissociated the aggregated protein resulting in a successfully folded, soluble, stable and structured molecule produced in high yield, which was protective against S. mansoni, thereby paving the way for its industrial production down track [ 45 ].…”

Section: Schistosoma Mansoni and S Haematobium mentioning

confidence: 99%

Schistosomiasis vaccines: where do we stand?

et al. 2016

View full text Add to dashboard Cite

Schistosomiasis, caused mainly by S. mansoni, S. haematobium and S. japonicum, continues to be a serious tropical disease and public health problem resulting in an unacceptably high level of morbidity in countries where it is endemic. Praziquantel, the only drug currently available for treatment, is unable to kill developing schistosomes, it does not prevent re-infection and its continued extensive use may result in the future emergence of drug-resistant parasites. This scenario provides impetus for the development and deployment of anti-schistosome vaccines to be used as part of an integrated approach for the prevention, control and eventual elimination of schistosomiasis. This review considers the present status of candidate vaccines for schistosomiasis, and provides some insight on future vaccine discovery and design.

show abstract

Refolding of the recombinant protein Sm29, a step toward the production of the vaccine candidate against schistosomiasis

Cited by 14 publications

References 42 publications

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

Current status and future prospects of protein vaccine candidates against Schistosoma mansoni infection

Schistosomiasis vaccines: where do we stand?

Contact Info

Product

Resources

About